Working with its Directors and Advisors including some of the world's leading experts in glaucoma and retinal disease, Galimedix has developed optimized clinical study designs for cost effective and Phase 2 proof of concept in both indications, offering multiple milestones in the near term pointing to a path to product registration.
Alexander Gebauer, M.D., Ph.D.
Executive Chairman, Managing Director OMEICOS Therapeutics GmbH,CEO OMEICOS Ophthalmics Inc.
Dr. Gebauer has more than 25 years industry experience in research and development, which led to numerous approvals worldwide in several therapeutic areas. He also holds the positions of managing director and CDO of Omeicos Therapeutics, a Berlin-based biotech company. Before that, he served in several R&D roles, including managing director, president of Global R&D, chief scientific officer and other positions at several international pharmaceutical companies including Sun Pharmaceuticals, Ranbaxy Laboratories, Ltd., Merz Pharmaceuticals, Hoechst AG, Aventis and Sanofi. Dr. Gebauer studied medicine at Johannes Gutenberg University, Mainz, Germany, where he completed his thesis in pharmacology. During his time at Merz, he served as senior vice president, head of Global Research & Development and was directly involved in the development programs of GAL-101 and GAL-201.
Andrew Pearlman, Ph.D.
Co-Founder, President, Board Member
Dr. Andrew Pearlman has more than 35 years’ experience founding and managing US/Israel biotechnology and medical device companies. A biophysicist, Dr. Pearlman has invented, licensed, developed and managed medical devices and biotechnologies from business and product concept through technology development, IP, prototyping, clinical trials, regulatory approval, manufacturing, and product sales. Dr. Pearlman has raised more than $120mm for new biomedical ventures he founded in Israel, including Medgenics, a gene therapy company he took from laboratory research stage through Phase 2 clinical trials and through IPOs on both the London Stock Exchange and the NYSE, building it to over $350 million in market cap. In less than one year, Dr. Pearlman founded Galimedix, built a world class team, and successfully completed a seed round of financing. Dr. Pearlman holds a Ph.D. in Biophysics from the University of California at Berkley (doctoral thesis under Nobel Laureates - Professors Melvin Calvin and Donald Glaser).
Jeffrey Liebmann, M.D.
Professor of Ophthalmology, Glaucoma Service Director, and Vice-Chair for the Department of Ophthalmology at Columbia University Medical Center.
Dr. Liebmann graduated from Boston University’s Combined Six-Year Medical Education Program in 1983, completed his ophthalmology residency at the State University of New York/Downstate Medical Center, and glaucoma fellowship training at the New York Eye and Ear Infirmary. Dr. Liebmann was previously Clinical Professor of Ophthalmology at New York University School of Medicine and Director of Glaucoma Services at Manhattan Eye, Ear, and Throat Hospital and New York University Langone Medical Center. Dr. Liebmann currently serves as President of the World Glaucoma Association, past-President of the American Glaucoma Society, Secretary-Treasurer of the New York Glaucoma Society, and co-editor of Journal of Glaucoma and is a member of the Board of Governors of the World Glaucoma Association and Boards of Directors of The Glaucoma Foundation and the American Glaucoma Society Foundation.
In addition to having one of the nation’s busiest tertiary-care glaucoma practices, Dr. Liebmann is also the Principal Investigator of the African Descent and Glaucoma Evaluation Study and is the author and/or co-author of more than 1,000 medical and scientific papers, book chapters, and abstracts. He has lectured widely in the United States and abroad on glaucoma diagnosis and management. His current main areas of research interest include the causes of glaucoma, glaucoma progression, glaucoma surgery, ocular imaging, and neuroprotection.
Ningli Wang, M.D., Ph.D.
Board Member, Director, Beijing Tongren Eye Center
Prof. Wang Ningli serves as the Director of Beijing Tongren Eye Center, Dean of School of Ophthalmology, Capital Medical University, Head of National Committee for the Prevention of Blindness, President-elect of Asia-Pacific Academy of Ophthalmology (APAO), President of Chinese Ophthalmologist Association, President of Chinese Society of Public Health Ophthalmology, Chair LXXIV of Academia Ophthalmologica Internationalis, Council Member of World Glaucoma Association, Board Member of Asia-Pacific Glaucoma Society, Emeritus Group Member of International Council of Ophthalmology.
He has published 429 peer-review papers as the first author or corresponding author, including 167 SCI articles, with 5388 citations in total and 4765 citations by others. Among his publications, 25 papers are published on articles (first author or corresponding author) the top two international ophthalmology journals; 4 papers are published on Nature Genetics and 1 paper on Nature Communication. In terms of the number of articles published in the glaucoma field, he ranks the first in China and top 10 worldwide. He is the chief-editor of 26 textbooks and monographs on ophthalmology and 12 standard specifications, and has been authorized 20 patents. As PI, he was awarded 2 National Science and Technology Progress Second Class Awards and 4 Provincial Science and Technology Progress First Class Awards. He was listed as Elsevier’s: “Most Cited Chinese Researchers” in 2014, 2015 and 2016, and The Ophthalmologist's “Top 100 most influential people in the world of ophthalmology” in 2014 and 2016).
Cary Sucoff, Esq.
Over 30 years of securities industry experience. Owns and operates Equity Source Partners, LLC, an advisory and consulting firm. Participated in financing hundreds of public and private companies, including biotech companies such as Amgen, Genzyme, Genentech, Icos, PathoGenesis, Contrafect, Medgenics and Galimedix. Boards of Directors for Contrafect Corp. (CFRX; Audit/Non-Gov), Galimedix Therapeutics, Inc. (Audit/Non-Gov), First Wave Technologies, Inc. and Legacy Education Alliance, Inc. (LEAI; Audit/ Non-Gov). Consultant to Sapience Therapeutics. Past President of New England Law, Member of the Board of Trustees for over 25 years and Chairman of the Endowment Committee. Member of the Bar of the State of New York (since 1978). BA from SUNY Binghamton and JD from New England School of Law (Managing Editor of the Law Review, graduated Magna Cum Laude).
Phyllis K. Bellin, M.B.A.
Chief Financial Officer
Ms. Bellin has more than 30 years' experience in founding and leading technology-based companies. Before joining Galimedix, she served as Vice President Finance & Administration, Corporate Secretary and Treasurer at Medgenics, Inc., leading IPOs on the London AIM and the NYSE. Previously, she was an officer at Citibank in Corporate Lending and Strategic Planning. Since moving to Israel in 1980, Ms. Bellin managed finance and administration for a number of early stage high-tech ventures in automotive safety, and health care. She was also Founder and Vice President of Gintec Active Safety Limited and responsible for finance and administration of its subsidiaries including RoadEye Limited. She served on the Board of Directors of the Misgav Economic Corporation and several private companies in Israel and the Netherlands. Ms. Bellin earned her MBA in Finance and Accounting from Columbia University, an MAT from the University of Chicago and a BA from Clark University.
Thomas C. Hohman, Ph.D.
Dr Thomas Hohman earned his Ph.D. at the University of California at Los Angeles and completed fellowships at the National Heart Blood and Lung Institute, and the National Eye Institute, National Institutes of Health, before beginning his career in drug development. At Wyeth-Ayerst, Dr Hohman led the aldose reductase inhibitor discovery program, advancing minalrestat into a clinical proof-of-concept (POC) study and establishing a GLP laboratory for quantifying clinical biomarkers for the long-term complications of diabetes. At Novartis Dr Hohman was the clinical lead for the development of ranibizumab as a treatment for exudative AMD and diabetic macular edema (DME). As the Retina Therapeutic Area Head at Alcon, Dr Hohman managed the development and clinical evaluation of a VEGFR2 tyrosine kinase inhibitor as a treatment for diabetic macular edema, designed a natural history study of geographic atrophy (GA) and used the data from this study to gain FDA, EMA and PMDA acceptance of atrophic lesion growth as a primary endpoint in studies of new therapeutics for GA; using this endpoint Dr Hohman evaluated a topically delivered serotonin 1A agonist as a potential treatment for geographic atrophy. As Vice President of Retina Translational Medicine and Head of Retina Drug Discovery at Allergan, Dr Hohman continued his studies of GA, managing a POC study and a multicenter Phase 2 study of a sustained-release formulation of brimonidine. In a parallel program Dr Hohman advanced a new biologics platform, designed ankyrin repeat proteins (DARPin) as a treatment for exudative age-related macular degeneration and led discovery efforts of complement inhibitors, as well as bi- and tri-specific DARPins, as the next generation of treatments for exudative AMD and diabetic retinopathy.
Following his retirement, Dr Hohman has continued his efforts to discover and develop new therapeutics by serving as a consultant to large and small pharmaceutical companies, as well as academicians engaged in the development of therapeutics to address unmet medical needs.